Functional Proteomics to Dissect Tyrosine Kinase Signalling Pathways in Cancer

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2010 Aug 20

PMID 20720570

Citations 84

Authors

Walter Kolch

Andrew Pitt

Affiliations

Soon will be listed here.

Abstract

Advances in the generation and interpretation of proteomics data have spurred a transition from focusing on protein identification to functional analysis. Here we review recent proteomics results that have elucidated new aspects of the roles and regulation of signal transduction pathways in cancer using the epidermal growth factor receptor (EGFR), ERK and breakpoint cluster region (BCR)-ABL1 networks as examples. The emerging theme is to understand cancer signalling as networks of multiprotein machines which process information in a highly dynamic environment that is shaped by changing protein interactions and post-translational modifications (PTMs). Cancerous genetic mutations derange these protein networks in complex ways that are tractable by proteomics.

Citing Articles

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy.

Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P Med Drug Discov. 2024; 23.

PMID: 39281823 PMC: 11393807. DOI: 10.1016/j.medidd.2024.100195.

Conjoint analysis of succinylome and phosphorylome reveals imbalanced HDAC phosphorylation-driven succinylayion dynamic contibutes to lung cancer.

Guo Y, Wen H, Chen Z, Jiao M, Zhang Y, Ge D Brief Bioinform. 2024; 25(5).

PMID: 39179249 PMC: 11343571. DOI: 10.1093/bib/bbae415.

MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells.

Tolue Ghasaban F, Ghanei M, Mahmoudian R, Taghehchian N, Abbaszadegan M, Moghbeli M Heliyon. 2024; 10(9):e30599.

PMID: 38726188 PMC: 11079401. DOI: 10.1016/j.heliyon.2024.e30599.

Development and Applications of Chimera Platforms for Tyrosine Phosphorylation.

Pergu R, Shoba V, Chaudhary S, Munkanatta Godage D, Deb A, Singha S ACS Cent Sci. 2023; 9(8):1558-1566.

PMID: 37637727 PMC: 10450875. DOI: 10.1021/acscentsci.3c00200.

Predicting anti-cancer drug combination responses with a temporal cell state network model.

Sarmah D, Meredith W, Weber I, Price M, Birtwistle M PLoS Comput Biol. 2023; 19(5):e1011082.

PMID: 37126527 PMC: 10174488. DOI: 10.1371/journal.pcbi.1011082.

References

Gan H, Kaye A, Luwor R . The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009; 16(6):748-54. DOI: 10.1016/j.jocn.2008.12.005. View

Persaud A, Alberts P, Amsen E, Xiong X, Wasmuth J, Saadon Z . Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol Syst Biol. 2009; 5:333. PMC: 2824488. DOI: 10.1038/msb.2009.85. View

Sawyers C . Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol. 1997; 10(2):223-31. DOI: 10.1016/s0950-3536(97)80004-2. View

Rauch J, ONeill E, Mack B, Matthias C, Munz M, Kolch W . Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res. 2010; 70(4):1679-88. PMC: 2880479. DOI: 10.1158/0008-5472.CAN-09-2740. View

Yang W, Di Vizio D, Kirchner M, Steen H, Freeman M . Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. Mol Cell Proteomics. 2009; 9(1):54-70. PMC: 2808267. DOI: 10.1074/mcp.M800448-MCP200. View

Faley S, Copland M, Wlodkowic D, Kolch W, Seale K, Wikswo J . Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells. Lab Chip. 2009; 9(18):2659-64. DOI: 10.1039/b902083g. View

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

Kruger M, Moser M, Ussar S, Thievessen I, Luber C, Forner F . SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell. 2008; 134(2):353-64. DOI: 10.1016/j.cell.2008.05.033. View

Brennan D, OConnor D, Rexhepaj E, Ponten F, Gallagher W . Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer. 2010; 10(9):605-17. DOI: 10.1038/nrc2902. View

10.

Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F . A module of negative feedback regulators defines growth factor signaling. Nat Genet. 2007; 39(4):503-12. DOI: 10.1038/ng1987. View

11.

Huang P, Mukasa A, Bonavia R, Flynn R, Brewer Z, Cavenee W . Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A. 2007; 104(31):12867-72. PMC: 1937558. DOI: 10.1073/pnas.0705158104. View

12.

Tiedemann R, Zhu Y, Schmidt J, Yin H, Shi C, Que Q . Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 2009; 115(8):1594-604. PMC: 2830764. DOI: 10.1182/blood-2009-09-243980. View

13.

Linscheid M, Ahrends R, Pieper S, Kuhn A . Liquid chromatography-mass spectrometry-based quantitative proteomics. Methods Mol Biol. 2009; 564:189-205. DOI: 10.1007/978-1-60761-157-8_11. View

14.

Wolf-Yadlin A, Sevecka M, MacBeath G . Dissecting protein function and signaling using protein microarrays. Curr Opin Chem Biol. 2009; 13(4):398-405. PMC: 2811369. DOI: 10.1016/j.cbpa.2009.06.027. View

15.

Irvine D, Heaney N, Holyoake T . Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data. Blood Rev. 2009; 24(1):1-9. DOI: 10.1016/j.blre.2009.11.002. View

16.

Wepf A, Glatter T, Schmidt A, Aebersold R, Gstaiger M . Quantitative interaction proteomics using mass spectrometry. Nat Methods. 2009; 6(3):203-5. DOI: 10.1038/nmeth.1302. View

17.

Cohen A, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A . Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008; 322(5907):1511-6. DOI: 10.1126/science.1160165. View

18.

Zhou Q, Chaerkady R, Shaw P, Kensler T, Pandey A, Davidson N . Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics. 2010; 10(5):1029-39. PMC: 3337220. DOI: 10.1002/pmic.200900602. View

19.

Irish J, Hovland R, Krutzik P, Perez O, Bruserud O, Gjertsen B . Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004; 118(2):217-28. DOI: 10.1016/j.cell.2004.06.028. View

20.

Kopf E, Zharhary D . Antibody arrays--an emerging tool in cancer proteomics. Int J Biochem Cell Biol. 2007; 39(7-8):1305-17. DOI: 10.1016/j.biocel.2007.04.029. View